ADORA2A and lung carcinoma: ADORA2A deficiency in GEMM in prostate and lung cancer could ablate NEtD process, and pharmacological inhibition blockade with ADORA2A antagonist SCH58261 also exhibited a promising antitumor effect in both NEPC and SCLC.